Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Embodiments of the present disclosure are directed to methods for recycling waste ion exchange materials comprising a first alkali metal salt and a second alkali metal salt comprising reducing the size of the waste ion exchange materials to produce a plurality of waste ion exchange particles having particle sizes from 0.10 mm to 5.0 mm, and regenerating the plurality of waste ion exchange particles to produce a plurality of regenerated ion exchange particles having a concentration of the first alkali metal salt greater than a concentration of the first alkali metal salt in the waste ion exchange materials. Systems for recycling a waste ion exchange materials comprising a first alkali metal salt and a second alkali metal salt are also disclosed.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A fining package for a glass composition may include cerium dioxide (CeO2) and tin oxide (SnO2). CeO2 may be present in an amount of 0.08 to 0.5 wt % of the glass composition, and SnO2 may be present in an amount of 0.02 to 0.23 wt % of the glass composition. The glass composition may be used to form glass tubing. The glass tubing may be used to form a pharmaceutical packaging. For example, the pharmaceutical packaging may comprise an ampoule. The fining package may further include chloride (Cl) in an amount of 0 to 0.03 wt % of the glass composition. In some instances, the fining package may be Cl-free. In some instances, the fining package may be F-free. The glass composition may comprise a borosilicate glass composition. The glass composition may comprise an aluminosilicate glass composition.

Abstract: The methods generally include contacting an alkali-containing glass article having a first alkali metal cation with a molten salt bath including from 0.1 wt. % to 3 wt. % nanoparticles and at least one alkali metal salt having a second alkali metal cation that has an atomic radius larger than an atomic radius of the first alkali metal cation. The nanoparticles may include at least one of metalloid oxide nanoparticles and metal oxide nanoparticles. The methods also include maintaining contact of the glass article with the molten salt bath to allow the first alkali metal cations to be exchanged with the second alkali metal cations of the molten salt bath. Further, the methods may include removing the glass article from contact with the molten salt bath to produce a strengthened glass article. A Surface Hydrolytic Resistance titration volume of the strengthened glass article may be less than 1.5 mL.

Abstract: Embodiments of a glass-based article including a first surface and a second surface opposing the first surface defining a thickness (t) of about 3 millimeters or less (e.g., about 1 millimeter or less), and a stress profile, wherein all points of the stress profile between a thickness range from about 0·t up to 0.3·t and from greater than about 0.7·t up to t, comprise a tangent with a slope having an absolute value greater than about 0.1 MPa/micrometer, are disclosed. In some embodiments, the glass-based article includes a non-zero metal oxide concentration that varies along at least a portion of the thickness (e.g., 0·t to about 0.3·t) and a maximum central tension in the range from about 80 MPa to about 100 MPa. In some embodiments, the concentration of metal oxide or alkali metal oxide decreases from the first surface to a value at a point between the first surface and the second surface and increases from the value to the second surface. The concentration of the metal oxide may be about 0.

Abstract: Embodiments of the present disclosure are directed to salt bath systems for strengthening glass articles including a salt bath tank defining a first interior volume enclosed by at least one sidewall; a salt bath composition including an alkali metal salt positioned within the first interior volume; a containment device defining a second interior volume enclosed by at least one sidewall and including a regeneration medium positioned within the second interior volume; and a circulation device positioned proximate to an inlet of the containment device, wherein the circulation device is operable to circulate the salt bath composition through the containment device. Methods for regenerating a molten salt are also disclosed.

Abstract: Embodiments of the present disclosure are directed to methods for recycling waste ion exchange materials comprising a first alkali metal salt and a second alkali metal salt comprising reducing the size of the waste ion exchange materials to produce a plurality of waste ion exchange particles having particle sizes from 0.10 mm to 5.0 mm, and regenerating the plurality of waste ion exchange particles to produce a plurality of regenerated ion exchange particles having a concentration of the first alkali metal salt greater than a concentration of the first alkali metal salt in the waste ion exchange materials. Systems for recycling a waste ion exchange materials comprising a first alkali metal salt and a second alkali metal salt are also disclosed.

Abstract: According to one embodiment, a glass article may include SiO2, Al2O3, Li2O and Na2O. The glass article may have a softening point less than or equal to about 810° C. The glass article may also have a high temperature CTE less than or equal to about 27×10?6/° C. The glass article may also be ion exchangeable such that the glass has a compressive stress greater than or equal to about 600 MPa and a depth of layer greater than or equal to about 25 ?m after ion exchange in a salt bath comprising KNO3 at a temperature in a range from about 390° C. to about 450° C. for less than or equal to approximately 15 hours.

Abstract: Embodiments described herein are directed to compositions, systems, and processes for strengthening glass articles, which also minimize the concentration of decomposition products in the molten salt baths used in ion exchange processes to extend salt bath life and maintain the chemical durability of strengthened glass articles over time. The salt bath compositions may generally include from 90 wt. % to 99.9 wt. % of one or more alkali or metal salts and from 0.1 wt. % to 10 wt. % of silicic acid aggregates based on the total weight of the salt bath composition.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.